anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Maintaining a balanced bile acids (BAs) metabolism is essential for lipid and cholesterol metabolism, as well as fat intake and absorption. The development of obesity may be intricately linked to BAs and their conjugated compounds. Our study aims to assess how BAs influence the obesity indicators by Mendelian randomization (MR) analysis. Instrumental variables of 5 BAs were obtained from public genome-wide association study databases, and 8 genome-wide association studies related to obesity indicators were used as outcomes. Causal inference analysis utilized inverse-variance weighted (IVW), weighted median, and MR-Egger methods. Sensitivity analysis involved MR-PRESSO and leave-one-out techniques to detect pleiotropy and outliers. Horizontal pleiotropy and heterogeneity were assessed using the MR-Egger intercept and Cochran Q statistic, respectively. The IVW analysis revealed an odds ratio of 0.94 (95% confidence interval: 0.88, 1.00; P = .05) for the association between glycolithocholate (GLCA) and obesity, indicating a marginal negative causal association. Consistent direction of the estimates obtained from the weighted median and MR-Egger methods was observed in the analysis of the association between GLCA and obesity. Furthermore, the IVW analysis demonstrated a suggestive association between GLCA and trunk fat percentage, with a beta value of -0.014 (95% confidence interval: -0.027, -0.0004; P = .04). Our findings suggest a potential negative causal relationship between GLCA and both obesity and trunk fat percentage, although no association survived corrections for multiple comparisons. These results indicate a trend towards a possible association between BAs and obesity, emphasizing the need for future studies.
Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
<P>PROBLEM TO BE SOLVED: To improve the efficiency of photographing work and to suppress the occurrence of hospital infection in photographing using a photographing device.  <P>SOLUTION: Portable terminals 10A, 10B and 10C, controllers 20A, 20B and 20C, communication terminals 10-1A, 10-1B and 10-1C, and medical image readers 30A, 30B and 30C are provided corresponding to respective floors A, B and C representing patient groups, respectively. In photographing order information transmitted to the controllers 20A, 20B and 20C from an information management device 60 through a network N and photographing order information set and inputted by the controllers 20A, 20B and 20C, photographing order information corresponding to each floor is extracted and respectively transmitted and displayed to/on the portable terminals 10A, 10B and 10C. This allows the controllers to transmit photographing order information corresponding to a prescribed patient group to a portable terminal corresponding to the same patient group, and the portable terminal receives and displays the photographing order information. Because of this, a patient photographer can photographs the patient on the basis of the photographing order information displayed corresponding to the prescribed patient group to improve the efficiency of photographing work.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
Systematic research into device-induced red blood cell (RBC) damage beyond hemolysis, including correlations between hemolysis and RBC-derived extracellular vesicles, remains limited. This study investigated non-physiological shear stress-induced RBC damage and changes in related biochemical indicators under two blood pump clinical support conditions. Pressure heads of 100 and 350 mmHg, numerical simulation methods, and two in vitro loops were utilized to analyze the shear stress and changes in RBC morphology, hemolysis, biochemistry, metabolism, and oxidative stress. The blood pump created higher shear stress in the 350-mmHg condition than in the 100-mmHg condition. With prolonged blood pump operation, plasma-free hemoglobin and cholesterol increased, whereas plasma glucose and nitric oxide decreased in both loops. Notably, plasma iron and triglyceride concentrations increased only in the 350-mmHg condition. The RBC count and morphology, plasma lactic dehydrogenase, and oxidative stress across loops did not differ significantly. Plasma extracellular vesicles, including RBC-derived microparticles, increased significantly at 600 min in both loops. Hemolysis correlated with plasma triglyceride, cholesterol, glucose, and nitric oxide levels. Shear stress, but not oxidative stress, was the main cause of RBC damage. Hemolysis alone inadequately reflects overall blood pump-induced RBC damage, suggesting the need for additional biomarkers for comprehensive assessments.
Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
This study is an ancillary of APPRENTICE. This will be the international based study. The initial study design with discussions about the different variables to be included into our prospective database started during 2014 PancreasFest held in Pittsburgh, PA in late July 2014 under the sponsorship of Collaborative Alliance for Pancreatic Education and Research (CAPER). Following this, a datasheet with variables was created, distributed through the initial participants, and further suggestions and edits were made. We now plan to move ahead with a web based seminar. All previous participants, as well as new investigators/centers that have shown interest in participating throughout the world will be invited.University of Pittsburgh will be responsible for collecting all required regulatory documents from other sites. Developing templates for questionnaires and other data collection forms. Will train approved sites on procedures. The coordinating center will be the recipient of de-identified data and will not be involved in the collection of data.

Note that copies of training records, licenses, certificates should be maintained in the study regulatory binder and are subject to audit by the Research Conduct and Compliance Office (RCCO).
<P>PROBLEM TO BE SOLVED: To provide a composition inhibiting the proliferation of cancer cells, especially breast cancer, hepatic cancer, lung cancer or stomach cancer cells, thus useful for treating and diagnosing tumors.  <P>SOLUTION: A pharmaceutical is provided, containing a curatively effective amount of an antibody(especially, monoclonal antibody, antibody fragments, chimeric antibody, humanized antibody) that expresses effects through bonding to a polypeptide which comprises a specific amino acid sequence or an amino acid sequence where one or several amino acids are substituted, deleted or added in the above amino acid sequence and is excessively expressed in breast cancer, hepatic cancer, lung cancer or stomach cancer cells. Another version of this pharmaceutical is such that the above antibody is conjugated with a cytotoxic agent(e.g. maytansinoid, calicheamicin). A kit including an immunohistochemically analytical means that diagnoses the presence of tumor using the above antibody is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Efficiency of walking and the development of independent gait are often the focus of therapeutic interventions for children with CP. Motor learning theory suggests that when encountering a new motor skill or adapting a motor skill to a specific situation, a group of interconnected neurons is selected from a primary neuronal repertoire based on prior experience of the task. Generated movement patterns and postural adjustments are then refined via afferent feedback. Therefore, it has been argued that to develop and improve a motor skill such as walking, opportunities for repetitive practice of the skill need to be offered. For this reason use of a mechanical treadmill may improve walking in children with CP. Treadmill walking provides increased opportunity to repetitively train the whole gait cycle, facilitate an improved gait pattern. Improved walking has the potential to increase the mobility and positively influence the societal participation of children with CP at home, at school and in the wider community.
PURPOSE: A novel RNA aptamer having anti-cancer effects and a pharmaceutical composition for treating cancers are provided to be used for diagnosing or treating cancers in which proteins are expressed. CONSTITUTION: A novel RNA aptamer combines with Lin28 or Lin28B protein. The RNA aptamer is selected from a group consisting of nucleotide sequence described in the sequence number 1(SEQ ID NO:1)-29. The cancer diagnostic kit includes the RNA aptamer. The cancer diagnostic kit additionally includes a container for performing and analyzing buffer solutions and detection. A pharmaceutical composition for treating cancers includes RNA aptamer as an active ingredient. The pharmaceutical composition for treating cancers additionally includes a pharmaceutically allowed carrier. A screening method of gene fragment which interacts with Lin28 or Lin28B comprises the following steps: withdrawing common base sequence which is included in the RNA aptamer; searching new gene fragment which includes the common sequence; and selecting the gene fragment which interacts with the Lin28 or Lin28B.
AIM: Standardised enteral nutrition protocols are recommended in critical care, however their use and safety are not well described in other inpatient populations. This mixed methods study reports on the use and safety of enteral nutrition protocols for non-critically ill adults.
METHODS: A scoping review of published literature was conducted. In addition a retrospective audit of practice at an Australian tertiary teaching hospital with an existing hospital-wide standardised enteral nutrition protocol was performed. Data on use, safety and adequacy of enteral nutrition prescription were collected from medical records for patients receiving enteral nutrition on acute wards (January-March 2020).
RESULTS: Screening of 9298 records yielded six primary research articles. Studies were generally low quality. Published literature suggested that protocols may reduce time to enteral nutrition initiation and goal rate, and improve adequacy of nutrition provision. No adverse outcomes were reported. From the local audit of practice (105 admissions, 98 patients), enteral nutrition commencement was timely (median 0 (IQR 0-1) days from request; goal rate: median 1 (IQR 0-2) days from commencement and adequate (nil underfeeding), without prior dietitian review in 82% of cases. Enteral nutrition was commenced per protocol in 61% of instances. No adverse events, including refeeding syndrome, were observed.
CONCLUSIONS: Most inpatients requiring enteral nutrition can be safely and adequately managed on enteral nutrition protocols. Evaluation of protocols outside of the critical care setting remains a gap in the literature. Standardised enteral nutrition protocols may improve delivery of nutrition to patients, whilst allowing dietitians to focus on those with specialised nutrition support needs.
The invention provides application of an epidermal growth factor in preparing a medicament for treating gastric ulcer. The EGF is extracted from artificial or natural sources, including EGF, HEGF, rhEGF, sh-EGF, rh-oligopeptides-1, and sh-oligopeptides-1. The medicine is a medical composition comprising an active agent, an auxiliary agent, a dispersing agent, a wetting agent and/or a suspending agent. The carrier of the epidermal growth factor is water, colloid, hyaluronic acid, natural oil and/or glucose. The medicine is one of capsule, tablet or oral liquid. The invention also provides application of the epidermal growth factor in preparing food for promoting health of digestive tract. The invention provides an application of Epidermal Growth Factor (EGF) in gastric ulcer treatment and gastrointestinal tract health care.
Objective: To conduct a comparative study of radiological and clinical outcomes between percutaneous transfacet screw (TFS) and pedicle screw (BPS) in oblique lateral lumbar interbody fusion (OLIF) for single-level lumbar spinal stenosis. Methods: A retrospective cohort study. Patients who underwent OLIF with TFS or BPS for the treatment of single-level lumbar spinal stenosis at Beijing Jishuitan Hospital from January 2019 to June 2022 were retrospectively analyzed. Radiological parameters and clinical indicators were compared between the two groups. Radiological parameters included preoperative, immediate postoperative (within 5 days), and 1-year postoperative measurements of disc height and segmental lordosis angle, as well as interbody fusion status at 1 year postoperatively. Clinical indicators included operative time, blood loss, length of hospital stay, complications, and Oswestry Disability Index (ODI), visual analogue scale (VAS) scores for back pain, and leg pain before and 1 year after surgery. Results: Four male and 10 female patients with an average age of (61.0±11.2) years underwent OLIF with TFS, while 9 male and 12 female patients underwent OLIF with BPS, with a mean age of (60.9±6.7) years. There was no statistically significant difference in preoperative disc height between the TFS and BPS groups (P>0.05). The immediate postoperative disc height was (12.9±2.1) mm and it was (10.4±1.7) mm at 1-year follow-up in the TFS group; in the BPS group, it was (12.9±2.1) mm immediately postoperatively and (11.9±2.1) mm at 1-year follow-up; there was statistically significant difference between the two groups at 1-year follow-up (P=0.037). The segmental lordosis angle showed no significant differences within each group or between the two groups at preoperative, immediate postoperative, or 1-year postoperative follow-up (all P>0.05). At 1-year postoperative follow-up, the fusion rates was 92.9%(13/14) in the TFS group and 95.2%(20/21) in the BPS group, with no statistically significant difference between the two groups (P>0.05). The TFS group had a significantly shorter operative time and less blood loss compared to the BPS group [(164.3±33.9) minutes vs (191.7±31.8) minutes and (74.3±46.9) ml vs (124.8±54.0) ml, respectively] (both P<0.05). Both groups showed significant improvement in ODI and VAS scores at 1 year postoperatively compared to those preoperatively, but with no statistically significant difference was found between the groups (both P>0.05). Conclusions: OLIF with TFS fixation can effectively restore disc height and alleviate back and leg pain in patients with single-level lumbar spinal stenosis. Compared to the OLIF with BPS procedure, OLIF with TFS has shorter operative time and less blood loss.
Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical combined preparation consisting of two hormonal preparations packaged separately in the space relationship in a single package unit and designated for oral administration in sequential time order that can be taken out separately as daily dosed units. The first of hormonal components has estrogenic gestagenic preparation in combination as hormonal biologically active substance taken in the dose that is sufficient for suppression of ovulation and made as monophase or multiphase variant. The second hormonal component has a single estrogenic preparation as hormonal biologically active substance. The first hormonal component has 23 or 25 and the second hormonal component has 4-10 daily dosed units and daily dosed units of the first hormonal component do not contain the combination of biogenic estrogen and synthetic estrogen. The total amount of daily dosed units of hormones is equal to the total amount of days of menstrual cycle. This combined preparation using for control of ability of women to make progeny has low estrogen content in each dosed unit and the total low content of hormones per cycle intaking and shows high contraception efficiency, insignificant cases of follicle development, faultless control of cycle and safety avoiding intermediate bleedings and nondesirable adverse effects. EFFECT: enhanced effectiveness of preparation. 6 cl, 1 ex
Epidemiological studies have shown that HPV-related diseases are the most prevalent sexually transmitted infections. In this context, this report will present various clinical cases demonstrating the effectiveness of Acyclovir (ACV) or its prodrug Valaciclovir (VCV), both acyclic guanosine analogs commonly used for the treatment of HHV-1 and HHV-2, for the treatment of HPV-related diseases. The report shows the remission of five cases of penile condyloma and a case of remission in a woman affected by cervical and vaginal condylomas and a vulvar giant condyloma acuminate of Buschke and Lowenstein. The literature review shows that ACV is effective in treating skin warts when administered orally, topically, and intralesionally, suggesting its therapeutic potential in other diseases associated with HPV. ACV was also used successfully as an adjuvant therapy for juvenile and adult forms of laryngeal papillomatosis, also known as recurrent respiratory papillomatosis, prolonging the patient's symptom-free periods. Although the prevention of HPV infections is certainly achieved with the HPV vaccine, ACV and VCV have shown to be effective even against genotypes not included in the current vaccine and can be helpful for those problematic clinical cases involving unvaccinated individuals, immunocompromised patients, people who live with HIV, or non-responders to the vaccine. We and others concluded that randomized clinical trials are necessary to determine the efficacy of ACV and VCV for HPV-related diseases.
Interregional free-trade of agricultural products is expected to transfer embodied (virtual) water from more to less water-productive regions. However, irrigation in semi-arid to arid regions may significantly push up agricultural productivity but cause local water scarcity. This may result in a puzzle: inter-regional trade may save overall water consumption but lead to more severe local water scarcity. An analogous puzzle may exist for farmland, for instance, trade may save farmland but not address farmland scarcity. To test the existence of these two important puzzles, we applied environmentally extended multi-regional input-output models to obtain the inter-regional virtual agricultural water and land transfer across 48 states of the conterminous U.S. and estimated their agricultural land and water footprints in 2017. Such a detailed analysis showed that while the land-abundant Midwestern states exported a sizable amount of virtual farmland to other densely populated areas and foreign nations, the water-stressed Western U.S. and Southwestern U.S. states, like California, Arizona, and New Mexico, exported considerable amounts of water-intensive crops such as fruits, vegetables and tree nuts to the Eastern U.S. and overseas, thus worsen the local water scarcity of those water scarce states. Our analysis highlights a critical dilemma inherent in an economic productivity-focused incentive regime: It frequently leads to increased withdrawal of scarce water. Therefore, resource scarcity rents need to be reflected in inter-regional trade with the support of local environmental policies.
Some of the most powerful tools to combat depression come in the form of psychotherapies, including Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT). While both treatments have been found to be generally effective in treating depression, they take fundamentally different treatment approaches. In CBT, clients learn techniques to challenge and change maladaptive thought and behavioral patterns. In ACT, clients learn techniques to accept their negative internal experiences and commit to action in line with their values. Despite being among the most effective treatments for depression, both CBT and ACT have a response rate of about only 50%. It is believe there are two key reasons investigators have not been able to improve these response rates. First, very little is known about which specific therapeutic skills are effective in these treatment packages. For example, do cognitive or behavioral change skills lead to therapeutic change in CBT? In ACT, do acceptance or change skills lead to therapeutic change? Second, it is not known which specific treatments or therapeutic skills work better for different individuals. Every individual has diverse needs, and therefore individuals may benefit differently from different treatment packages or from specific skills within each package.

Therefore, investigators plan to run a randomized controlled trial comparing CBT and ACT for depression in order to investigate which specific therapeutic skills are effective in these treatment packages. This approach will also allow investigators to identify predictors of differential response to treatment packages and specific treatment skills.

Upon joining the study, participants are asked to complete surveys for one week prior to starting treatment and again for one week once treatment is completed. During treatment, they are asked to complete surveys throughout the 8 weeks of therapy. Following the 8-week treatment, participants are asked to complete monthly follow-up surveys for 6 months.

There are three main objectives in this study. The first is to compare processes of change across the two treatments (i.e., what works in specific treatments?). The second is to determine client variables that predict differential treatment response (i.e., which treatment works best for a given client?). The third is to evaluate potential moderators of differential response to any specific skills across the treatments (i.e., which specific therapy skill works best for a given client?)
Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.